Long-term results from the IDEAL-CRT phase 1/2 trial of isotoxically dose-escalated radiation therapy and concurrent chemotherapy for stage II/III non-small cell lung cancer

118 patients with stage IIB-IV non-small cell lung cancer were treated with isotoxically-escalated concurrent chemoradiotherapy, to median prescribed doses of 64.5 and 67.6 Gy in 30 fractions over 5 (N=36) or 6 weeks (N=82). Toxicity was acceptable for both schedules. Overall survival was longer in 6-week than 5-week patients (median 41.2 versus 22.1 months; HR=0.56, 95%CI: 0.32-0.98, p=0.04). Progression-free survival was also longer in 6-week patients (median 21.1 versus 8.0 months; HR=0.53, 95%CI: 0.33-0.86, p=0.01).

Source: International Journal of Radiation Oncology * Biology * Physics - December 2, 2019 Category: Radiology Authors: J.D. Fenwick, D.B. Landau, A. Baker, A.T. Bates, C. Eswar, A. Garcia-Alonso, S.V. Harden, M.C. Illsley, V. Laurence, Z. Malik, W.P.M. Mayles, E. Miles, N. Mohammed, J. Spicer, P. Wells, S. Vivekanandan, A.M. Mullin, L. Hughes, L. Farrelly, Y. Ngai, N. Cou Source Type: research